This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Hideaki Sato
President and CEO at Luxna Biotech


In March 2004, after leaving Kyoto University Graduate School of Agriculture, Department of Applied Life Sciences, he joined Gene Design Co., Ltd. as a researcher. After working as the general manager of Technical Service and Marketing Division and executive officer, I became the business director and acted as a counter to the acquisition by Ajinomoto . I was involved in the CpG-ODN clinical development as a malaria vaccine adjuvant. Luxna Biotech Co., Ltd., a start-up company from Osaka University (Co-founder Professor Satoshi Obika), and assumed the position of President in February 2018, and currently serves as President and CEO. I'm secretary of the Regulatory Science Subcommittee of the Nucleic Acid Therapeutics Society of Japan.

Agenda Sessions

  • Novel Findings of Suitable Gapmer Modification for Neurological Application and Our Preclinical Progress of Sub-acute Spinal Cord Injury Treatment Drug Development